NVCR
NovoCure Limited
NVCR has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
NVCR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
NVCR's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NVCR PE Valuation
NVCR has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
NVCR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
NVCR has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
NVCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.06 | +$0.55 |
| Q2 2026 | -$1.30 | +$0.26 |
| Q1 2026 | -$1.53 | -$0.02 |
| Q4 2025 | -$1.22 | +$0.34 |
| Q3 2025 | -$1.61 | -$0.21 |
| Q2 2025 | -$1.56 | +$0.02 |
| Q1 2025 | -$1.51 | +$0.30 |
| Q4 2024 | -$1.56 | +$0.39 |
NVCR is still losing money, but less than at its worst: $1.06 per share over the past year, against $1.95 at its worst in late 2023.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over NVCR on earnings quality, reporting a profit while its opponent remains loss making.
NVCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $193.4M | +16% |
| Q2 2026 | $183.6M | +16% |
| Q1 2026 | $174.1M | +12% |
| Q4 2025 | $174.4M | +8.1% |
| Q3 2025 | $167.2M | +7.8% |
| Q2 2025 | $158.8M | +5.6% |
| Q1 2025 | $155M | +12% |
| Q4 2024 | $161.3M | +21% |
NVCR's revenue has grown year over year for 12 quarters in a row: $193M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.2% | +18 points |
| Q2 2026 | -5.8% | +19 points |
| Q1 2026 | -39% | -14 points |
| Q4 2025 | -23% | +16 points |
| Q3 2025 | -22% | -0.8 points |
| Q2 2025 | -25% | -2.6 points |
| Q1 2025 | -24% | +5.6 points |
| Q4 2024 | -39% | -0.6 points |
NVCR's operating margin was −3.2% last quarter, up 18 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over NVCR on profitability, with a higher operating margin.
NVCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $15.7M | +5.5% |
| Q2 2026 | $1.2M | +$22.6M |
| Q1 2026 | -$18.7M | +$27.6M |
| Q4 2025 | -$22.9M | -$10.5M |
| Q3 2025 | $14.9M | +$15.2M |
| Q2 2025 | -$21.4M | -$8.3M |
| Q1 2025 | -$46.3M | -$2.9M |
| Q4 2024 | -$12.4M | +$9M |
NVCR's free cash flow was −$25M over the past year, against −$65M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over NVCR on cash generation, producing positive trailing cash flow while its opponent burns cash.
NVCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +773K shares |
| 1 year | +4.4% | +4.9M shares |
| 3 years | +9.4% | +10M shares |
| 5 years | +13% | +13.1M shares |
| Available history | +8.2% | +8.9M shares |
NVCR has 117M diluted shares, up 4.4% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over NVCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
NVCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2021 | -105.8x | Net Cash |
| Q2 2021 | 8.7x | High |
| Q1 2021 | 5.7x | High |
| Q4 2020 | 4.9x | High |
| Q3 2020 | -8.5x | Net Cash |
| Q2 2020 | -2.9x | Net Cash |
| Q1 2020 | -3.2x | Net Cash |
| Q4 2019 | -3.7x | Net Cash |
NVCR has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
NVCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.6 | Neutral |
| Stochastic | 14.2 | Oversold |
NVCR's weekly RSI is 38 (neutral) and its Stochastic is 14 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
NVCR PE vs Healthcare Sector
| Metric | NVCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NVCR has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NVCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.0 | 16% below |
| 20 week MA | $15.6 | 25% below |
| 50 week MA | $14.5 | 19% below |
| 100 week MA | $16.0 | 27% below |
| 200 week MA | $23.3 | 50% below |
NVCR is in a downtrend: it's below all five of its weekly moving averages, and 50% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over NVCR on trend strength, trading above more of its moving averages.
NVCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $87.6 | $172.0 | +96% |
| 2021 | $172.0 | $84.0 | -51% |
| 2022 | $84.0 | $73.0 | -13% |
| 2023 | $73.0 | $14.9 | -80% |
| 2024 | $14.9 | $30.7 | +106% |
| 2025 | $30.7 | $13.5 | -56% |
| 2026 YTD | $13.5 | $11.7 | -13% |
NVCR has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.